Many of the 75 million Americans with essential hypertension also develop diabetes and other complications in addition to their high blood pressure, and researchers have discovered a common molecular mechanism in a strain of rat that explains why such metabolic disorders arise together in mammals.
Ads by Google
InterCure announced the findings of new studies and analysis highlighting RESPeRATE -- the only medical device cleared by the FDA and CE-approved for the treatment of hypertension. Five posters will be presented at the European Society of Hypertension meeting (ESH) in Berlin beginning June 14, 2008. Two of the five posters focus on RESPeRATE's effect on blood pressure as measured by 24-hour ambulatory blood pressure monitoring. Three of the posters also present new findings in the emerging field of obtaining vascular risk parameters from blood pressure measurements.
Hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, titled VIOS (Vascular Improvement with Olmesartan medoxomil Study) was a one-year, exploratory study that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.
More than 70 percent of patients identified as having "high normal" systolic blood pressure through traditional cuff blood pressure measurement may be at serious cardiovascular risk.
Everyone at risk for high blood pressure should monitor it regularly at home to give a clear picture of blood pressure changes and to make it possible for doctors to give proper treatment for every patient.
Managing high blood pressure requires to monitor hypertension regularly and individuals that have high blood pressure need to monitor it in timely manner, says the American Heart Association, American Society of Hypertension and the Preventive Cardiovascular Nurses' Association.
Two different studies find that treating blood pressure in mild sleep apnea patients may cut heart risk.
Daiichi Sankyo's data demonstrated that the powerful combination drug AZOR safely and effectively helped patients across several major subpopulations lower their blood pressure.